Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile

Rifamycins are widely used for treating mycobacterial and staphylococcal infections. Drug-drug interactions (DDI) caused by rifampicin (RIF) are a major issue. We used a model-based approach to predict the magnitude of DDI with RIF and rifabutin (RBT) for 217 cytochrome P450 (CYP) substrates. On average, DDI caused by low-dose RIF were twice as potent as those caused by RBT. Contrary to RIF, RBT appears unlikely to cause severe DDI, even with sensitive CYP substrates.

Mots clés

Drug-drug interaction Pharmacokinetics Rifabutin Rifampicin

Domaines

Microbiologie et Parasitologie Pharmacologie

Nolwenn Retiveau : Connectez-vous pour contacter le contributeur

https://hal.science/hal-03633663

Soumis le : jeudi 7 avril 2022-10:33:57

Dernière modification le : lundi 17 juin 2024-16:26:31

Dates et versions

hal-03633663 , version 1 (07-04-2022)

Identifiants

HAL Id : hal-03633663 , version 1
DOI : 10.1128/AAC.01043-21
PUBMED : 34228545
PUBMEDCENTRAL : PMC8370242
WOS : 000707901200048

Citer

Vianney Tuloup, Mathilde France, Romain Garreau, Nathalie Bleyzac, Laurent Bourguignon, et al.. Model-Based Comparative Analysis of Rifampicin and Rifabutin Drug-Drug Interaction Profile. Antimicrobial Agents and Chemotherapy, 2021, 65 (9), pp.e0104321. ⟨10.1128/AAC.01043-21⟩. ⟨hal-03633663⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

HCL CNRS UNIV-LYON1 BIOENVIS LBBE UDL

54 Consultations

0 Téléchargements